Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;15(4):342–363. doi: 10.1111/j.1750-3639.2005.tb00119.x

Angiogenesis in Gliomas: Imaging and Experimental Therapeutics

Jean‐Pierre Gagner 1,2,3, Meng Law 4,5,6, Ingeborg Fischer 1,2,3, Elizabeth W Newcomb 2,6, David Zagzag 1,2,3,5,6,✉
PMCID: PMC8095871  PMID: 16389946

Abstract

Much of the interest in angiogenesis and hypoxia has led to investigating diagnostic imaging methodologies and developing efficacious agents against angiogenesis in gliomas. In many ways, because of the cytostatic effects of these agents on tumor growth and tumor‐associated endothelial cells, the effects of therapy are not immediately evident. Hence finding clinically applicable imaging tools and pathologic surrogate markers is an important step in translating glioma biology to therapeutics. There are a variety of strategies in the approach to experimental therapeutics that target the hypoxia‐inducible factor pathway, the endogenous antiangiogenic and proangiogenic factors and their receptors, adhesion molecules, matrix proteases and cytokines, and the existing vasculature. We discuss the rationale for antiangiogenesis as a treatment strategy, the preclinical and clinical assessment of antiangiogenic interventions and finally focus on the various treatment strategies, including combining antiangiogenic drugs with radiation and chemotherapy.

Full Text

The Full Text of this article is available as a PDF (1,001.0 KB).

References

  • 1. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE (2003) Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890–8898. [PubMed] [Google Scholar]
  • 2. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML (1998) Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low‐grade astrocytoma. J Neurosurg 88:513–520. [DOI] [PubMed] [Google Scholar]
  • 3. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, Laterra J (2002) In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribo‐zymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 16:108–110. [DOI] [PubMed] [Google Scholar]
  • 4. Acker T, Diez‐Juan A, Aragones J, Tjwa M, Brus‐selmans K, Moons L, Fukumura D, Moreno‐Mur‐ciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchin M, Jain RK, Plate KH, Carmeliet P (2005) Genetic evidence for a tumor suppressor role of HIF‐2a. Cancer Cell 8:131–141. [DOI] [PubMed] [Google Scholar]
  • 5. Akella NS, Twieg DB, Mikkelsen T, Hochberg FH, Grossman S, Cloud GA, Nabors LB (2004) Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 20:913–922. [DOI] [PubMed] [Google Scholar]
  • 6. An H, Lin W (2000) Quantitative measurements of cerebral blood oxygen saturation using magnetic resonance imaging. J Cereb Blood Flow Metab 20:1225–1236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Anderson SA, Glod J, Arbab AS, Noel M, Ashari P, Fine HA, Frank JA (2005) Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105:420–425. [DOI] [PubMed] [Google Scholar]
  • 8. Arrieta O, Guevara P, Tamariz J, Rembao D, Rivera E, Sotelo J (2002) Antiproliferative effect of tha‐lidomide alone and combined with carmustine against C6 rat glioma. Int J Exp Pathol 83:99–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Barth RF, Wu G, Yang W, Binns PJ, Riley KJ, Pa‐tel H, Coderre JA, Tjarks W, Bandyopadhyaya AK, Thirumamagal BTS, Ciesielski MJ, Fenstermaker RA (2004) Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC‐C225) as a delivery agent. Appl Radiat Isot 61:899–903. [DOI] [PubMed] [Google Scholar]
  • 10. Baumann F, Bjeljac M, Kollias SS, Baumert BG, Brandner S, Rousson V, Yonekawa Y, Bernays RL (2004) Combined thalidomide and temozolo‐mide treatment in patients with glioblastoma multiforme. J Neurooncol 67:191–200. [DOI] [PubMed] [Google Scholar]
  • 11. Bello L, Lucini V, Carrabba G, Giussani C, Machluf M, Pluderi M, Nikas D, Zhang J, Tomei G, Villani RM, Carroll RS, Bikfalvi A, Black PM (2001) Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase‐2. Cancer Res 61:8730–8736. [PubMed] [Google Scholar]
  • 12. Bello L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Tomei G, Villani R, Scaglione F, Carroll RS, Bikfalvi A (2002) Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 8:3539–3548. [PubMed] [Google Scholar]
  • 13. Bello L, Lucini V, Giussani C, Carrabba G, Pluderi M, Scaglione F, Tomei G, Villani R, Black PM, Bikfalvi A, Carroll RS (2003) IS201, a specific av(33 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 52:177–186. [DOI] [PubMed] [Google Scholar]
  • 14. Bello L, Giussani C, Carrabba G, Pluderi M, Costa F, Bikfalvi A (2004) Angiogenesis and invasion in gliomas. Cancer Treat Res 117:263–284. [DOI] [PubMed] [Google Scholar]
  • 15. Bello L, Lucini V, Costa F, Pluderi M, Giussani C, Acerbi F, Carrabba G, Pannacci M, Caronzolo D, Grosso S, Shinkaruk S, Colleoni F, Canron X, Tomei G, Deleris G, Bikfalvi A (2004) Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin Cancer Res 10:4527–4537. [DOI] [PubMed] [Google Scholar]
  • 16. Benes L, Kappus C, McGregor GP, Bertalanffy H, Mennel HD, Hagner S (2004) The immunohis‐tochemical expression of calcitonin receptor‐like receptor (CRLR) in human gliomas. J Clin Pathol 57:172–176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Bengtson NW, Linzer DI (2000) Inhibition of tumor growth by the antiangiogenic placental hormone, proliferin‐related peptide. Mol Endocri-nol 14:1934–1943. [DOI] [PubMed] [Google Scholar]
  • 18. Benjamin R, Capparella J, Brown A (2003) Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 9:82–90. [DOI] [PubMed] [Google Scholar]
  • 19. Bernsen HJ, Rijken PF, Oostendorp T, van der Kogel AJ (1995) Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer 71:721–726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Bernsen HJJA, Rijken PFJW, Peters JPW, Bak‐ker H, van der Kogel A (1998) Delayed vascular changes after antiangiogenic therapy with anti‐vascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 43:570–575. [DOI] [PubMed] [Google Scholar]
  • 21. Bhujwalla ZM, Artemov D, Natarajan K, So‐laiyappan M, Kollars P, Kristjansen PEG (2003) Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP‐470. Clin Cancer Res 9:355–362. [PubMed] [Google Scholar]
  • 22. Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus J, Weber KJ, Huber PE (2004) Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60:1220–1232. [DOI] [PubMed] [Google Scholar]
  • 23. Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM (2000) Design of GFB‐111, a platelet‐derived growth factor binding molecule with antiangiogenic and an‐ticancer activity against human tumors in mice. Nat Biotech 18:1065–1070. [DOI] [PubMed] [Google Scholar]
  • 24. Blum R, Jacob‐Hirsch J, Amariglio N, Rechavi G, Kloog Y (2005) Ras inhibition in glioblastoma down‐regulates hypoxia‐inducible factor‐la, causing glycolysis shutdown and cell death. Cancer Res 65:999–1006. [PubMed] [Google Scholar]
  • 25. Bogdanov A Jr, Marecos E, Cheng HC, Chan‐drasekaran L, Krutzsch HC, Roberts DD, Weissled‐er R (1999) Treatment of experimental brain tumors with thrombospondin‐1 derived peptides: an in vivo imaging study. Neoplasia 1:438–445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R (2000) Imaging of tumour neovasculature by targeting the TGF‐beta binding receptor endoglin. Eur J Cancer 36:675–681. [DOI] [PubMed] [Google Scholar]
  • 27. Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K (2003) Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepato‐cyte growth factor‐antagonist NK4. Clin Cancer Res 9:4578–4585. [PubMed] [Google Scholar]
  • 28. Broholm H, Laursen H (2004) Vascular endothelial growth factor (VEGF) receptor neuropi‐lin‐1's distribution in astrocytic tumors. APMIS 112:257–263. [DOI] [PubMed] [Google Scholar]
  • 29. Brower V (1999) Tumor angiogenesis–new drugs on the block. Nat Biotechnol 17:963–968. [DOI] [PubMed] [Google Scholar]
  • 30. Bu X, Khankaldyyan V, Gonzales‐Gomez I, Groshen S, Ye W, Zhuo S, Pons J, Stratton JR, Rosenberg S, Laug WE (2004) Species‐specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab Invest 84:667–678. [DOI] [PubMed] [Google Scholar]
  • 31. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH (2003) Dynamic, contrast‐enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. Magn Reson Med 49:848–855. [DOI] [PubMed] [Google Scholar]
  • 32. Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber M, Lu S, Zagzag D (2000) Dynamic, contrast‐enhanced T2*‐weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. Am J Neuroradiol 21:881–890. [PMC free article] [PubMed] [Google Scholar]
  • 33. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP (2005) Differentiation of low‐grade oligodendrogliomas from low‐grade astrocyto‐mas by using quantitative blood‐volume measurements derived from dynamic susceptibility contrast‐enhanced MR Imaging. Am J Neuroradiol 26:266–273. [PMC free article] [PubMed] [Google Scholar]
  • 34. Chakravarti A, Dicker A, Mehta M (2004) The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlate clinical data. Int J Radiat Oncol Biol Phys 58:927–931. [DOI] [PubMed] [Google Scholar]
  • 35. Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W Jr, Mehta M (2005) Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncocology Group. Int J Radiat Oncol Biol Phys 62:318–327. [DOI] [PubMed] [Google Scholar]
  • 36. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, Rabbitt J, Page M, Nicholas MK, Prados MD (2004) Phase II study of temozolo‐mide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353–357. [DOI] [PubMed] [Google Scholar]
  • 37. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, de Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute (2005) Phase II study of CCI‐779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361. [DOI] [PubMed] [Google Scholar]
  • 38. Christoforidis GA, Grecula JC, Newton HB, Kangarlu A, Abduljalil AM, Schmalbrock P, Chakeres DW (2002) Visualization of microvascularity in glioblastoma multiforme with 8‐T high‐spa‐tial‐resolution MR imaging. Am J Neuroradiol 23:1553–1556. [PMC free article] [PubMed] [Google Scholar]
  • 39. Ciafrè SA, Barillari G, Bongiorno‐Borbone L, Wannenes F, Izquierdo M, Farace MG (2002) A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo. Gene Ther 9:297–302. [DOI] [PubMed] [Google Scholar]
  • 40. Ciafrè SA, Niola F, Wannenes F, Farace MG (2004) An anti‐VEGF ribozyme embedded within the adenoviral VAI sequence inhibits glioblastoma cell angiogenic potential in vitro. J Vasc Res 41:220–228. [DOI] [PubMed] [Google Scholar]
  • 41. Collins TS, Hurwitz HI (2005) Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32:61–68. [DOI] [PubMed] [Google Scholar]
  • 42. Corada M, Zanetta L, Orsenigo F, Breviario F, Lampugnani MG, Bernasconi S, Liao F, Hicklin DJ, Bohlen P, Dejana E (2002) A monoclonal antibody to vascular endothelial‐cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100:905–911. [DOI] [PubMed] [Google Scholar]
  • 43. Costouros NG, Diehn FE, Libutti SK (2002) Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl 39:72–78. [DOI] [PubMed] [Google Scholar]
  • 44. Daumas‐Duport C, Scheithauer B, O'Fallon J, Kelly P (1988) Grading of astrocytomas: a simple and reproducible method. Cancer 62:2152–2165. [DOI] [PubMed] [Google Scholar]
  • 45. de Boüard S, Guillamo JS, Christov C, , Le‐févre Brugières P , Gola E, Devanz P, Indraccolo S, Peschanski M (2003) Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon‐α, angiostatin, or endostatin. Hum Gene Ther 14:883–895. [DOI] [PubMed] [Google Scholar]
  • 46. de Boüard S, Guillamo JS (2005) [Angiogenesis and anti‐angiogenic strategies for glioblasto‐mas] Bull Cancer 92:360–372. [PubMed] [Google Scholar]
  • 47. Degani H, Chetrit‐Dadiani M, Bogin L, Furman‐Haran E (2003) Magnetic resonance imaging of tumor vasculature. Thromb Haemost 89:23–33. [PubMed] [Google Scholar]
  • 48. Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen‐Jonathan E (2003) The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloprotease 2 expression in human glioma xenograft. Clin Cancer Res 9:6062–6068. [PubMed] [Google Scholar]
  • 49. Donnelly EF, Geng L, Wojcicki WE, Fleischer AC, Hallahan DE (2001) Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 219:166–170. [DOI] [PubMed] [Google Scholar]
  • 50. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393. [PubMed] [Google Scholar]
  • 51. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O (2001) Tumor vasculature is targeted by the combination of combretastatin A‐4 and hyperthermia. Radiother Oncol 61:313–320. [DOI] [PubMed] [Google Scholar]
  • 52. Evans SM, Judy KD, Dunphy, I , Jenkins T, Nelson PT, Collins R, Wileyto EP, Jenkins K, Hahn SM, Stevens CW, Judkins AR, Phillips P, Geoerger B, Koch CJ (2004) Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64:1886–1892. [DOI] [PubMed] [Google Scholar]
  • 53. Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P (2005) Combined inhibition of vascular endothelial growth factor and platelet‐derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 102:363–370. [DOI] [PubMed] [Google Scholar]
  • 54. Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G, Kiss R (2000) Characterization of TNP‐470‐induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol Meth 43:15–24. [DOI] [PubMed] [Google Scholar]
  • 55. Feldkamp MM, Lau N, Roncari L, Guha A (2001) Isotype‐specific Ras‐GTP‐levels predicts the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 61:4425–4431. [PubMed] [Google Scholar]
  • 56. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high‐grade gliomas. J Clin Oncol 21:2299–2304. [DOI] [PubMed] [Google Scholar]
  • 57. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of Temsirolimus (CCI‐779) in recurrent glioblastoma multiforme: North Central Cancer Treatment Group. J Clin Oncol 23:5294–5304. [DOI] [PubMed] [Google Scholar]
  • 58. Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. J Clin Oncol 23:1295–1311. [DOI] [PubMed] [Google Scholar]
  • 59. Geng L, Donnelly E, McMahon G, Lin PC, Sierra‐Rivera E, Oshinka H, Hallahan DE (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413–2419. [PubMed] [Google Scholar]
  • 60. Gilhuis HJ, Bernsen HJJA, Jeuken JWM, Wesselin P, Sprenger SHA, Kerstens HMJ, Wiegant J, Boerman RH (2001) The relationship between genetic aberrations as detected by comparative genomic hybridization and vascularization in glioblastoma xenografts. J Neurooncol 51:121–127. [DOI] [PubMed] [Google Scholar]
  • 61. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625. [PubMed] [Google Scholar]
  • 62. Goldbrunner RH, Bendszus M, Tonn JC (2004) Models for angiogenesis in gliomas. Cancer Treat Res 117:115–135. [DOI] [PubMed] [Google Scholar]
  • 63. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC (2004) PTK787/ ZK222584, an inhibitor of vascular endothelial growth factor receptor kinases, decreases glioma growth and vascularization. Neurosurgery 55:426–432. [DOI] [PubMed] [Google Scholar]
  • 64. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS (2004) RNAi‐mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23:8486–8496. [DOI] [PubMed] [Google Scholar]
  • 65. Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Tung CH, Weissleder R, Rao JS (2004) Adenovirus‐mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64:4069–4077. [DOI] [PubMed] [Google Scholar]
  • 66. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR (1999) Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378. [PubMed] [Google Scholar]
  • 67. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavence WK, Wang XF, Bigner DD, Friedman HS, Rich JN (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101–112. [PubMed] [Google Scholar]
  • 68. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thorton D (2005) The protein kinase Cbetaselective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65:7462–7469. [DOI] [PubMed] [Google Scholar]
  • 69. Griscelli F, Li H, Cheong C, Opolon P, Bennaceur‐Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P (2000) Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A 97:6698–6703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Haas‐Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887. [DOI] [PubMed] [Google Scholar]
  • 71. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A, Bikfalvi A (2005) Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci U S A 102:1643–1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Heidenreich R, Machein M, Nicolaus A, Hilbig A, Wild C, Clauss M, Plate KH, Breier G (2004) Inhibition of solid tumor growth by gene transfer ofVEGF receptor‐1 mutants. Int J Cancer 111:348–357. [DOI] [PubMed] [Google Scholar]
  • 74. Herschman HR (2003) Molecular imaging: looking at problems, seeing solutions. Science 302:605–608. [DOI] [PubMed] [Google Scholar]
  • 75. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN (2004) SB‐431542, a small molecule transforming growth factor‐β‐receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 3:737–745. [PubMed] [Google Scholar]
  • 76. Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WK, Kang JK (2000) Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon‐beta treatment at early stage of tumor development. Clin Cancer Res 6:3354–3360. [PubMed] [Google Scholar]
  • 77. Hou H, Grinberg OY, Grinberg SA, Demidenko E, Swartz HM (2005) Cerebral tissue oxygenation in reversible focal ischemia in rats: multi‐site EPR oximetry measurements. Physiol Meas 26:131–141. [DOI] [PubMed] [Google Scholar]
  • 78. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ (2004) Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2:36–42. [PubMed] [Google Scholar]
  • 79. Im SA, Gomez‐Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK (1999) Antiangiogenesis treatment for gliomas: transfer of antisense‐vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59:895–900. [PubMed] [Google Scholar]
  • 80. Ivanov S, Liao SY, Ivanova A, DanilkovitchMiagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia‐inducible cell‐surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62. [DOI] [PubMed] [Google Scholar]
  • 82. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJF (2004) Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 45:143–163. [DOI] [PubMed] [Google Scholar]
  • 83. Joe YA, Hong YK, Chung DS, Yang YJ, Kang JK, Lee YS, Chang SI, You WK, Lee H, Chung SI (1999) Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1–3. Int J Cancer 82:694–699. [DOI] [PubMed] [Google Scholar]
  • 84. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, Black PM (2001) Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotech 19:35–39. [DOI] [PubMed] [Google Scholar]
  • 85. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S (1999) Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area‐specific CGH on microdissected tumor cells. J Neuropath Exp Neurol 58:993–999. [DOI] [PubMed] [Google Scholar]
  • 86. Kamiyana H, Takano S, Tsuboi K, Matsumura A (2005) Anti‐angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxiainducible factor 1 alpha (HIF‐1α)/ vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131:205–213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Kaur G, Belotti D, Burger AM, Fisher‐Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R (2004) Antiangiogenic properties of 17‐(dimethylaminoethylamino)‐17‐demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 10:4813–4821. [DOI] [PubMed] [Google Scholar]
  • 88. Kee HJ, Ahn KY, Choi KC, Won Song J, Heo T, Jung S, Kim JK, Bae CS, Kim KK (2004) Expression of brain‐specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia‐induced brain angiogenesis and malignant glioma. FEBS Lett 569:307–316. [DOI] [PubMed] [Google Scholar]
  • 89. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–737. [DOI] [PubMed] [Google Scholar]
  • 90. Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, LaFleur B, Dressman D, Stephan DA, MacDonald TJ (2003) Overexpression of the EGFR/FKBP12/HIF‐2α pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 63:1865–1870. [PubMed] [Google Scholar]
  • 91. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR (2003) Tumour‐endothelium interactions in co‐culture: coordinated change of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–1022. [DOI] [PubMed] [Google Scholar]
  • 92. Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL (2003) Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 160:662–666. [DOI] [PubMed] [Google Scholar]
  • 93. Kirsch M, Schackert G, Black PM (2000) Antiangiogenic treatment strategies for malignant brain tumors. J Neurooncol 50:149–163. [DOI] [PubMed] [Google Scholar]
  • 94. Kitange GJ, Templeton KL, Jenkins RB (2003) Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15:197–2003. [DOI] [PubMed] [Google Scholar]
  • 95. Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, Miller DC, Kelly PJ, Kricheff, II (1999) Glial neoplasms: dynamic contrast‐enhanced T2*‐weighted MR imaging. Radiology 211:791–798. [DOI] [PubMed] [Google Scholar]
  • 96. Kortmann RD, Jeremic B, Weller M, Plasswilm L, Bamberg M (2003) Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 179:219–232. [DOI] [PubMed] [Google Scholar]
  • 97. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD (2001) Vascular endothelial growth factor receptor‐2‐blocking antibody potentiates radiation‐induced long‐term control of human tumor xenografts. Cancer Res 61:39–44. [PubMed] [Google Scholar]
  • 98. Kragh M, Quistorff B, Tenan M, van Meir EG, Kristjansen PE (2002) Overexpression of thrombospondin‐1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res 62:1191–1195. [PubMed] [Google Scholar]
  • 99. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor‐2. Cancer Res 61:6624–6628. [PubMed] [Google Scholar]
  • 100. Lafuente JV, Adan B, Alkiza K, Garibi JM, Rossi M, Cruz‐Sanchez FF (1999) Expression of vascular endothelial growth factor (VEGF) and platelet‐derived growth factor receptor‐beta (PEDGFR‐beta) in human gliomas. J Mol Neurosci 13:177–185. [DOI] [PubMed] [Google Scholar]
  • 101. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TAT, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160. [PubMed] [Google Scholar]
  • 102. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS (2004) Inhibition of cathepsin B and MMP‐9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23:4681–4689. [DOI] [PubMed] [Google Scholar]
  • 103. Lakka SS, Gondi CS, Dinh DH, Olivero WC, Gujrati M, Rao VH, Sioka C, Rao JS (2005) Specific interference of urokinase‐type plasminogen activator receptor and matrix metalloproteinase‐9 gene expression induced by double‐stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 280:21882–21892. [DOI] [PubMed] [Google Scholar]
  • 104. Lal B, Xia S, Abounader R, Laterra J (2005) Targeting the c‐Met pathway potentiates glioblastoma responses to y‐radiation. Clin Cancer Res 11:4479–4486. [DOI] [PubMed] [Google Scholar]
  • 105. Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti‐angiogenic glioma therapy. Acta Neurochir 88(suppl):169–177. [DOI] [PubMed] [Google Scholar]
  • 106. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF‐A. Clin Cancer Res 9:1399–1405. [PubMed] [Google Scholar]
  • 107. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor‐2, epidermal growth factor receptor, and vascular endothelial‐cadherin. Clin Cancer Res 11:4934–4940. [DOI] [PubMed] [Google Scholar]
  • 108. Larson DA, Prados M, Lamborn KR, Smith V, Sneed PK, Chang S, Nicholas KM, Wara WM, Devriendt D, Kunwar S, Berger M, McDermott MW (2002) Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54:1397–1404. [DOI] [PubMed] [Google Scholar]
  • 109. Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR, NABTT CNS Consortium study (2004) Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro-Oncol 6:15–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Law M, Brodsky J, Babb J, Rosenblum M, Johnson G, Zagzag D (2005) Correlating increased cerebral blood volume measurements in human gliomas with 1 p and 19q molecular deletions. Proc ASNR, Toronto 489:269. [Google Scholar]
  • 111. Law M, Meltzer DE, Wetzel SG, Yang S, Knopp EA, Golfinos J, Johnson G (2004) Conventional MR imaging with simultaneous measurements of cerebral blood volume and vascular permeability in ganglioglioma. Magn Reson Imaging 22:599–606. [DOI] [PubMed] [Google Scholar]
  • 112. Law M, Oh S, Brodsky J, Babb J, Johnson G, Zagzag D (2005) Imaging molecular markers of hypoxia in glioblastoma multiforme with MR spectroscopic imaging and dynamic susceptibility contrast perfusion MRI. Proc ASNR, Toronto 184:96. [Google Scholar]
  • 113. Law M, Oh S, Wang E, Babb J, Inglese M, Knopp E, Zagzag D, Johnson G (2005) Dynamic susceptibility contrast perfusion MR imaging of low‐grade gliomas: Prediction of patient clinical response. Radiology in Press. [DOI] [PubMed] [Google Scholar]
  • 114. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24:1989–1998. [PMC free article] [PubMed] [Google Scholar]
  • 115. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast‐enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol 25:746–755. [PMC free article] [PubMed] [Google Scholar]
  • 116. Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10:3216–3224. [DOI] [PubMed] [Google Scholar]
  • 117. Lehnhardt FG, Rohn G, Ernestus RI, Grune M, Hoehn M (2001) 1H and (31) P‐MR Spectroscopy of primary and recurrent human brain tumors in vitro: malignancy‐ characteristic profiles of water soluble and lipophilic spectral components. NMR Biomed 14:307–317. [DOI] [PubMed] [Google Scholar]
  • 118. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GRt, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG (2004) Glial tumor grading and outcome prediction using dynamic spin‐echo MR susceptibility mapping compared with conventional contrast‐enhanced MR: confounding effect of elevated rCBV of oli‐godendrogliomas [corrected]. Am J Neuroradiol 25:214–221. [PMC free article] [PubMed] [Google Scholar]
  • 119. Lev MH, Rosen BR (1999) Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 9:309–331. [PubMed] [Google Scholar]
  • 120. Li X, Vigneron DB, Cha S, Graves EE, Crawford F, Chang SM, Nelson SJ (2005) Relationship of MR‐derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. Am J Neuroradiol 26:760–769. [PMC free article] [PubMed] [Google Scholar]
  • 121. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102:5814–5819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Lund EL, Bastholm L, Kristjansen PEG (2000) Therapeutic synergy of TNP‐470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971–978. [PubMed] [Google Scholar]
  • 123. Lund EL, Høg A, Olsen MWB, Hansen LT, Engelholm SA, Kristjansen PEG (2004) Differential regulation of VEGF, HIF 1α and angiopoietin‐1, ‐2 and ‐4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 108:833–838. [DOI] [PubMed] [Google Scholar]
  • 124. Lupo JM, Cha S, Chang SM, Nelson SJ (2005) Dynamic susceptibility‐weighted perfusion imaging of high‐grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol 26:1446–1454. [PMC free article] [PubMed] [Google Scholar]
  • 125. Ma HI, Guo P, Li J, Lin SZ, Chiang YH, Xiao X, Cheng SY (2002) Suppression of intracranial human glioma growth after intramuscular administration of an adeno‐associated viral vector expressing angiostatin. Cancer Res 62:756–763. [PubMed] [Google Scholar]
  • 126. Ma J, Li S, Reed K, Guo P, Gallo JM (2003) Pharmacodynamic‐mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exper Ther 305:833–839. [DOI] [PubMed] [Google Scholar]
  • 127. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an av integrin antagonist. Neurosurgery 48:151–157. [DOI] [PubMed] [Google Scholar]
  • 128. Machein MR, Risau W, Plate KH (1999) Antiangiogenic gene therapy in a rat model using a dominant‐negative vascular endothelial growth factor receptor 2. Hum Gene Ther 10:1117–1128. [DOI] [PubMed] [Google Scholar]
  • 129. Machein MR, Renninger S, de Lima‐Hahn E, Plate KH (2003) Minor contribution of bone marrow‐derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 13:582–597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Maia AC, Jr. , Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, Stavale JN (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol 26:777–783. [PMC free article] [PubMed] [Google Scholar]
  • 131. Maintz D, Heindel W, Kugel H, Jaeger R, Lackner KJ (2002) Phosphorus‐31 MR Spectroscopy of normal adult human brain and brain tumors. NMR Biomed 15:18–27. [DOI] [PubMed] [Google Scholar]
  • 132. Marquez A, Wu R, Zhao J, Tao J, Shi Z (2004) Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright‐field microscopy. Diagn Mol Pathol 13:1–8. [DOI] [PubMed] [Google Scholar]
  • 133. McCarty MF, Liu W, Fan F, Parikh A, Reimuth N, Stoeltzing O, Ellis LM (2003) Promises and pitfalls of anti‐angiogenic therapy in clinical trials. Trends Mol Med 9:53–58. [DOI] [PubMed] [Google Scholar]
  • 134. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J (1992) Treatment and survival of low‐grade astrocytoma in adults‐1977–1988. Neurosurgery 31:636–642; discussion 642. [DOI] [PubMed] [Google Scholar]
  • 135. Mentlein R, Eichler O, Forstreuter F, HeldFeindt J (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer 92:545–550. [DOI] [PubMed] [Google Scholar]
  • 136. Mentlein R, Held‐Feindt J (2003) Angiogenesis factors in gliomas: a new key to tumour therapy. Naturissenschaften 90:385–394. [DOI] [PubMed] [Google Scholar]
  • 137. Mentlein R, Forstreuter F, Mehdorn HM, HeldFeindt J (2004) Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. J Neurooncol 67:9–18. [DOI] [PubMed] [Google Scholar]
  • 138. Miraux S, Lemière S, Pineau R, Pluderi M, Canioni P, Franconi JM, Thiaudière E, Bello L, Bikfalvi A, Auguste P (2004) Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin‐regulated expression system. Angiogenesis 7:105–113. [DOI] [PubMed] [Google Scholar]
  • 139. Mischel PS, Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13:52–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140. Mishima K, Mazar AP, Gown A, Skelly M, Ji XD, Wang XD, Jones TR, Cavenee WK, Huang HJS (2000) A peptide derived from the non‐receptorbinding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A 97:8484–8489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141. Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Vo‐land JR, Old LJ, Huang HJS, Cavenee WK (2001) Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349–5354. [PubMed] [Google Scholar]
  • 142. Nabeshima K, Shimao Y, Sato S, Kataoka H, Moriyama T, Kawano H, Wakisaka S, Koono M (1997) Expression of c‐Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31:436–443. [DOI] [PubMed] [Google Scholar]
  • 143. Nakamura M, Ishida E, Shimada K, Kishi M, Sasaki T, Konishi N (2005) Frequent LOH on 22q 12.3 and TIMP‐3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85:165–175. [DOI] [PubMed] [Google Scholar]
  • 144. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinitymatured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15:1271–1275. [DOI] [PubMed] [Google Scholar]
  • 145. Newcomb EW (2004) Flavopiridol: pleiotropic biological effects enhance its anti‐cancer activity. Anti-Cancer Drugs 15:411–419. [DOI] [PubMed] [Google Scholar]
  • 146. Newcomb EW, Ali MA, Schnee T, Lan L, Lukyanov Y, Fowkes M, Miller DC, Zagzag D (2005) Flavopiridol downregulates hypoxia‐mediated hypoxia‐inducible factor‐1 alpha expression in human glioma cells by a proteasome‐independent pathway: implications for in vivo therapy. Neuro-Oncol 7:225–235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147. Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967–3979. [DOI] [PubMed] [Google Scholar]
  • 148. Ochs JS (2004) Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 58:941–949. [DOI] [PubMed] [Google Scholar]
  • 149. Ogawa S, Lee TM, Kay AR, Tank DW (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci U S A 87:9868–9872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150. Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brunner N, Martin PM (2002) Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 160:1279–1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 151. Padhani AR (2005) BOLD MRI and PET Imaging of Tumor Oxygenation. Proc of ISMRM 13:176. [Google Scholar]
  • 152. Pearson DA, Lister J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, Dean RT (1996) Thrombus imaging using technetium‐99m‐labeled highpotency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies. J Med Chem 39:1372–1382. [DOI] [PubMed] [Google Scholar]
  • 153. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z (2004) Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery 55:562–568. [DOI] [PubMed] [Google Scholar]
  • 154. Piepmeier JM, Christopher S (1997) Lowgrade gliomas: introduction and overview. J Neurooncol 34:1–3. [DOI] [PubMed] [Google Scholar]
  • 155. Piepmeier JM (1987) Observations on the current treatment of low‐grade astrocytic tumors of the cerebral hemispheres. J Neurosurg 67:177–181. [DOI] [PubMed] [Google Scholar]
  • 156. Platten M, Wick W, Weller M (2001) Malignant glioma biology: role of TGF‐β in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52:401–410. [DOI] [PubMed] [Google Scholar]
  • 157. Pluderi M, Lucini V, Caronzolo D, Pannacci M, Costa F, Carrabba G, Giussani C, Grosso S, Colleoni F, Scaglione F, Villani R, Bikfalvi A, Bello L (2003) Long‐term inhibition of glioma growth by systemic administration of human PEX. J Neurosurg Sci 47:69–78. [PubMed] [Google Scholar]
  • 158. Powis G, Kirkpatrick L (2004) Hypoxia‐inducible factor‐1α as a cancer drug target. Mol Cancer Ther 3:647–654. [PubMed] [Google Scholar]
  • 159. Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP (2004) MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20:865–873. [DOI] [PubMed] [Google Scholar]
  • 160. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG (2002) Comparison of permeability in high‐grade and low‐grade brain tumors using dynamic susceptibility contrast MR imaging. Am J Roentgenol 178:711–716. [DOI] [PubMed] [Google Scholar]
  • 161. Puduvalli VK (2004) Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 117:307–336. [DOI] [PubMed] [Google Scholar]
  • 162. Rajan B, Pickuth D, Ashley S, Traish D, Monro P, Elyan S, Brada M (1994) The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys 28:405–413. [DOI] [PubMed] [Google Scholar]
  • 163. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3:489–501. [DOI] [PubMed] [Google Scholar]
  • 164. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G (2002) Identification of small molecule inhibitors of hypoxia‐inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316–4324. [PubMed] [Google Scholar]
  • 165. Rapisarda A, Zalek J, Hollingstead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule‐dependent inhibition of hypoxia‐inducible factor‐lα protein accumulation, angiogenesis, and tumor growth by topotecan in U251‐HRE glioblastoma xenografts. Cancer Res 64:6854–6848. [DOI] [PubMed] [Google Scholar]
  • 166. Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P (2001) Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate‐encapsulated cells. Cancer Res 61:6830–6837. [PubMed] [Google Scholar]
  • 167. Rege TA, Fears CY, Gladson CL (2005) Endogenous inhibitors of angiogenesis in malignant gliomas: Nature's antiangiogenic therapy. NeuroOncology 7:106–121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430–446. [DOI] [PubMed] [Google Scholar]
  • 169. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt‐Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142. [DOI] [PubMed] [Google Scholar]
  • 170. Rijken PFJW, Bernsen HJJA, Peters JPW, Hodgkiss RJ, Raleigh JA, van der Kogel AJ (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi‐parameter analysis. Int J Rad Oncol Biol Phys 48:571–582. [DOI] [PubMed] [Google Scholar]
  • 171. Roberts HC, Roberts TPL, Brasch RC, Dillon WP (2000) Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast‐enhanced MR Imaging: Correlation with histologic grade. Am J Neuroradiol 21:891–899. [PMC free article] [PubMed] [Google Scholar]
  • 172. Roberts WG, Whalen PM, Doderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E (2005) Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP‐673,451. Cancer Res 65:957–966. [PubMed] [Google Scholar]
  • 173. Robinson SP, Howe FA, Rodrigues LM, Stubbs M, Griffiths JR (1998) Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. Semin Radiat Oncol 8:197–207. [DOI] [PubMed] [Google Scholar]
  • 174. Robinson SP, Collingridge DR, Howe FA, Rodrigues LM, Chaplin DJ, Griffiths JR (1999) Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed 12:98–106. [DOI] [PubMed] [Google Scholar]
  • 175. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti‐VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA (2003) Targeting the over‐expressed urokinase‐type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 65:63–75. [DOI] [PubMed] [Google Scholar]
  • 177. Saleh M, Davis ID, Wilks AF (1997) The paracrine role of tumour‐derived mIL‐4 on tumourassociated endothelium. Int J Cancer 72:664–672. [DOI] [PubMed] [Google Scholar]
  • 178. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH (1999) Effect of in situ retroviral interleukin‐4 transfer on established intracranial tumors. J Natl Cancer Inst 91:438–445. [DOI] [PubMed] [Google Scholar]
  • 179. Saleh M, Jonas NK, Wiegmans A, Stylli SS (2000) The treatment of established intracranial tumors by in situ retroviral IFN‐γ transfer. Gene Ther 7:1715–1724. [DOI] [PubMed] [Google Scholar]
  • 180. Salibi N, Brown MA (1998) Clinical MR Spectroscopy. New York : John Wiley & Sons. [Google Scholar]
  • 181. Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, Stopa EG (2004) Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Contr 11:174–180. [DOI] [PubMed] [Google Scholar]
  • 182. Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim AT, Henriksson R (2004) The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 19:1174–1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 183. Sasaki M, Wizigmann‐Voos S, Risau W, Plate KH (1999) Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int J Dev Neurosci 17:579–591. [DOI] [PubMed] [Google Scholar]
  • 184. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, Schmidt K, Albert M, Black PM, Carroll RS. (2004) Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficacy and survival in an orthotopic human glioblastoma model. Clin Cancer Res 10:1255–1262. [DOI] [PubMed] [Google Scholar]
  • 185. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63:4009–4016. [PubMed] [Google Scholar]
  • 186. Schuuring J, Bussink J, Bernsen HJ, Peeters W, van der Kogel AJ (2005) Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 61:529–534. [DOI] [PubMed] [Google Scholar]
  • 187. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P (2003) A phase I study of SR‐4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 9:5101–5112. [PubMed] [Google Scholar]
  • 188. Semenza GL (2003) Targeting HIF‐1 for cancer therapy. Nat Rev Cancer 3:721–732. [DOI] [PubMed] [Google Scholar]
  • 189. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878:236–270. [DOI] [PubMed] [Google Scholar]
  • 190. Shannon AM, Bouchier‐Hayes DJ, Condron CM, Toomey D (2003) Tumour hypoxia, chemotherapy resistance and hypoxia‐related therapies. Cancer Treat Rev 29:297–307. [DOI] [PubMed] [Google Scholar]
  • 191. Sharma S, Sharma MC, Sarkar C (2005) Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46:481–489. [DOI] [PubMed] [Google Scholar]
  • 192. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC (2004) Dose‐dependent effects of platelet‐derived growth factor‐B on glial tumorigenesis. Cancer Res 64:4783–4789. [DOI] [PubMed] [Google Scholar]
  • 193. Shin JH, Lee HK, Kwun BD, Kim J‐S, Kang W, Choi CG, Suh DC (2002) Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results . Am J Roentgenol 179:783–789. [DOI] [PubMed] [Google Scholar]
  • 194. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B (2005) Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24:5414–5422. [DOI] [PubMed] [Google Scholar]
  • 195. Short SC, Harney J (2003) Radiobiology and vascular targeting in glioma. Curr Opin Neurol 16:651–655. [DOI] [PubMed] [Google Scholar]
  • 196. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H (1998) Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58:2784–2792. [PubMed] [Google Scholar]
  • 197. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3‐targeted magnetic resonance imaging. Nat Med 4:623–626. [DOI] [PubMed] [Google Scholar]
  • 198. Sorensen DR, Leirdal M, Iversen PO, Sioud M (2002) Combination of endostatin and a protein kinase Ca DNA enzyme improves the survival of rats with malignant glioma. Neoplasia 4:474–479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR (1998) Adenoviral TNF‐alpha gene therapy and radiation damage tumor vasculature in a human glioma xenograft. Gene Ther 5:293–300. [DOI] [PubMed] [Google Scholar]
  • 200. Stan AC, Nemati MN, Pietsch T, Walter GF, Dietz H (1995) In vivo inhibition of angiogenesis and growth of the human U‐87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 82:1044–1052. [DOI] [PubMed] [Google Scholar]
  • 201. Steinbach JP, Klumpp A, Wolburg H, Weller M (2004) Inhibition of epidermal growth factor signaling protects human malignant glioma cells from hypoxia‐induced cell death. Cancer Res 164:1575–1578. [DOI] [PubMed] [Google Scholar]
  • 202. Su JD, Mayo LD, Donner DB, Durden DL (2003) PTEN and phosphatidylinositol 3′‐kinase inhibitors up‐regulate p53 and block tumor‐induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 63:3585–3592. [PubMed] [Google Scholar]
  • 203. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, Shigematsu Y, Liang L, Ge Y, Ushio Y, Takahashi M (1998) Correlation of MR imaging‐determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479–1486. [DOI] [PubMed] [Google Scholar]
  • 204. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek‐Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM (2004) Blocking angiogenesis and tumorigenesis with GFA‐116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 64:3586–3592. [DOI] [PubMed] [Google Scholar]
  • 205. Sund M, Xie L, Kalluri R (2004) The contribution of vascular basement membranes and extracellular matrix to the mechanic of tumor angiogenesis. APMIS 112:450–462. [DOI] [PubMed] [Google Scholar]
  • 206. Sundberg AL, Gedda L, Orlova A, Bruskin A, Blomquist E, Carlsson J, Tolmachev V (2004) [177Lu]Bz‐DTPA‐EGF: preclinical characterization of a potential radionuclide targeting agent against glioma. Cancer Biother Radiopharm 19:195–204. [DOI] [PubMed] [Google Scholar]
  • 207. Swartz HM (2005) EPR measurements of tissue oxygenation status. Proc ISMRM 13:178. [Google Scholar]
  • 208. Swartz HM, Khan N, Buckey J, Comi R, Gould L, Grinberg O, Hartford A, Hopf H, Hou H, Hug E, Iwasaki A, Lesniewski P, Salikhov I, Walczak T (2004) Clinical applications of EPR: overview and perspectives. NMR Biomed 17:335–351. [DOI] [PubMed] [Google Scholar]
  • 209. Taga T, Suzuki A, Gonzalez‐Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE (2002) αv‐integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690–697. [DOI] [PubMed] [Google Scholar]
  • 210. Tan C, de Noronha RG, Roecker AJ, ska Pyrzyn B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, van Meir EG (2005) Identification of a novel small‐molecule inhibitor of the hypoxia‐inducible factor 1 pathway. Cancer Res 65:605–612. [PubMed] [Google Scholar]
  • 211. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M (2001) Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 7:634–640. [PubMed] [Google Scholar]
  • 212. Tozer GM (2003) Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 76:S23–S35. [DOI] [PubMed] [Google Scholar]
  • 213. Tuettenberg J, Grobbolz R, Korn T, Wenz F, Erber R, Vajkoczy P (2005) Continuous low‐dose chemotherapy plus inhibition of cyclooxygen‐ase‐2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TAT (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk‐1 inhibitor SU5416 as assessed by intravital multi‐fluorescence videomicroscopy. Neoplasia 1:31–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 215. Vajkoczy P, Menger MD (2004) Vascular microenvironment in gliomas. Cancer Treat Res 117:249–262. [DOI] [PubMed] [Google Scholar]
  • 216. Vajkoczy P, Ullrich A, Menger MD (2000) Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia 2:53–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217. Verheul HMW, Voest EE, Schlingemann RO (2004) Are tumours angiogenesis‐dependent J Pathol 202:5–13. [DOI] [PubMed] [Google Scholar]
  • 218. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP (2005) Effect of the tumor vascular‐damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835–842. [PubMed] [Google Scholar]
  • 219. Weinmann M, Belka C, Plasswilm L (2004) Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 27:83–90. [DOI] [PubMed] [Google Scholar]
  • 220. Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219:316–333. [DOI] [PubMed] [Google Scholar]
  • 221. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP (2000) In vivo magnetic resonance imaging of transgene expression. Nat Med 6:351–355. [DOI] [PubMed] [Google Scholar]
  • 222. Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD (2002) Generation of anti‐idiotypic reagents in the EGFRvIII tumor‐associated antigen system. Cancer Immunol Immunother 50:639–652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223. Wild R, Dhanabal M, Olson TA, Ramakrishnan S (2000) Inhibition of angiogenesis and tumour growth by VEGF121‐toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer 83:1077–1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin‐1, and matrix metal‐loproteinases. Cancer Cell 6:553–563. [DOI] [PubMed] [Google Scholar]
  • 225. Wu W‐C, Chen C‐Y, Chung H‐W, Juan C‐J, Hsueh C‐J, Gao H‐W (2002) Discrepant MR spectroscopic and perfusion imaging results in a case of malignant transformation of cerebral glioma. Am J Neuroradiol 23:1775–1778. [PMC free article] [PubMed] [Google Scholar]
  • 226. Yanamandra N, Gumidyala KV, Waldron KG, Gujrati M, Olivero WC, Dinh DH, Rao JS, Moha‐nam S (2004) Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 23:2224–2230. [DOI] [PubMed] [Google Scholar]
  • 227. Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH, Rao JS (2005) Recombinant adeno‐associated virus (rAAV) expressing TFPI‐2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 115:998–1005. [DOI] [PubMed] [Google Scholar]
  • 228. Yang W, Barth RF, Wu G, Ciesielski MJ, Fenstermaker RA, Moffat BA, Ross BD, Wikstrand CJ (2005) Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 11:341–350. [PubMed] [Google Scholar]
  • 229. Yoshida D, Noha M, Watanabe K, Sugisaki Y, Teramoto A (2002) SI‐27, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity: detection with a variable‐pressure scanning electron microscope. Neurosurgery 50:578–586. 11841727 [Google Scholar]
  • 230. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time‐dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti‐vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93:14765–14770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231. Yung YC, Cheshier S, Santarelli JG, Huang Z, Wagers A, Weissman I, Tse V (2004) Incorporation of naïve bone marrow derived cells into the vascular architecture of brain tumor. Microcirculation 11:699–708. [DOI] [PubMed] [Google Scholar]
  • 232. Zadeh G, Qian B, Okhowat A, Sabha N, Kon‐tos CD, Guha A (2004) Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol 164:467–476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 233. Zagzag D, Nomura M, Friendlander DR, Blanco C, Gagner JP, Nomura N, Newcomb EW (2003) Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia‐inducible factor (HIF‐Iα) in glioma cell invasion. J Cell Physiol 196:394–402. [DOI] [PubMed] [Google Scholar]
  • 234. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia‐inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618. [PubMed] [Google Scholar]
  • 235. Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Lain G, Gionnet K, Goncalves M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A (2003) Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem 278:35564–35573. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES